Addictions are chronic brain diseases that can be treated medically
Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.
We are headquartered in Santa Monica, with additional offices in London, UK.
Statistics
Patient population with addictions and drug overdose
Over 20 million people are affected by addictions and drug overdose in the United States.
with emergency room visits with Acute Cannabinoid Overdose
with Alcohol Use Disorder
with Opioid Use Disorder and 48k opioid-related overdose deaths annually
PIPELINE
Our pipeline
In response to a growing public health need, Opiant is developing products to treat addictions and drug overdose.
Spotlight
The latest from Opiant
Fighting the Opioid Crisis – FOX Business
October 21, 2019 – Opiant CEO Roger Crystal on The Claman Countdown discusses the fight on the opioid crisis.
Fighting the Opioid Crisis – Fox Business Network’s “Mornings with Maria”
August 3, 2018 – Opiant CEO Dr. Roger Crystal discusses NARCAN® following singer Demi Lovato’s hospitalization.
Meeting of the President’s Commission on Combating Drug Addiction and Opioid Crisis
September 27, 2017 – Opiant CEO Dr. Roger Crystal testifies before the President’s Commission on Combating Drug Addiction and the Opioid Crisis.
Opiant Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
SANTA MONICA, Calif. , May 03, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and…
Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone
Pharmacodynamic study will compare OPNT003, nasal nalmefene, with nasal naloxone in reversing the respiratory depression produced by the synthetic opioid, remifentanil Top-line data expected in…
Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose
SANTA MONICA, Calif. , March 31, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions…
May 11, 2021 4:30 PM EDT : Opiant Pharmaceuticals First Quarter 2021 Financial Results and Corporate Update Conference Call
March 4, 2021 4:30 PM EST : Opiant Pharmaceuticals Fourth Quarter and Full Year 2020 Financial Results Conference Call
January 11, 2021 – January 15, 2021 : JP Morgan Healthcare Conference 2021
Cannabinoid1 (CB‐1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose
Published in 2020 by the Journal of Neural Transmission.
Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose
Published in April 2019 by ASPET Journals.
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects
Published in March 2019 by American College of Neuropsychopharmacology.
Lessons from a doctor and CEO on the US’s opioid crisis
April 14, 2020 – Roger Crystal set out to impact healthcare at a ‘societal’ level. The doctor who developed the NARCAN® Nasal Spray says he is proud to see its impact on the opioid crisis in the United States: the opioid overdose reversal medicine has saved a large number of lives.
Opiant donates to organizations supporting patients vulnerable to substance use disorders during COVID-19
Opiant donated $40,000 to the International Association of Fire Fighters Foundation, the Association of Recovery in Higher Education, the Harm Reduction Coalition and the UK’s Action on Addiction.